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The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system 2 
where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term 3 
potentiation and long-term depression. The endocannabinoid system (ECS) components - cannabinoid 4 
receptors, endocannabinoids and synthesis/degradation enzymes - are expressed and are functional from 5 
early developmental stages and throughout adolescence cortical development, regulating progenitor cell 6 
fate, neural differentiation, migration and survival. This may potentially confer increased vulnerability to 7 
adverse outcomes from early cannabinoid exposure. Cannabidiol (CBD) is one of the most studied 8 
exogenous cannabinoid, and CBD-enriched Cannabis extracts have been widely (and successfully) used 9 
as adjuvants to treat children with refractory epilepsy, and there is even an FDA-approved product with it. 10 
However, there is not sufficient evidence regarding potential detrimental consequences upon long term 11 
alterations in the central nervous system’s development by cannabinoids. As well as the majority of 12 
cannabinoids, CBD is able to exert its effects directly and indirectly through the ECS, which can perturb 13 
the regulatory processes mediated by this system. Besides, CBD has a large number of non-14 
endocannabinoid targets which can explain CBD’s effects. Here, we review the current knowledge about 15 
CBD-based therapies - pure and CBD-enriched Cannabis extracts - in studies with pediatric patients, its 16 
side effects, and its mechanisms of action regarding the central nervous system and neurodevelopment 17 
aspects. Since Cannabis extracts contain tetrahydrocannabinol (D9-THC), we consider that pure CBD is 18 
possibly safer for young patients. Nevertheless, CBD, as well as other natural and/or synthetic 19 
cannabinoids, should be studied in more detail as a therapeutic alternative to CBD enriched-Cannabis 20 
extracts during brain developmental stages. 21 
Key points 22 
• Cannabidiol (CBD) targets the endocannabinoid system directly via CB1 receptors, or indirectly 23 
by regulating endocannabinoids levels, in both developing and mature brains.  24 
• D9-THC is believed to be responsible for the majority of the potential harmful effects of CBD-25 
enriched Cannabis extracts, although further direct evaluation of the effects of CBD upon brain 26 
development are necessary. 27 
•  For young patients pure CBD, both synthetic or plant derived, produced in accordance with 28 
good manufacturing practices (GMP-grade), is recommended as a therapeutic option instead of 29 
   
 
   
 
3
CBD-enriched Cannabis extracts, and a recently a CBD-based (Epidiolex®) product was 1 
approved by FDA for the treatment of Dravet and Lennox-Gastaut syndromes. 2 
• There is a lack of trials of chronic administration of CBD-based therapies with long term follow-3 
up periods, which would allow a more realistic comparison of their effects with the current 4 
treatment options. 5 
 6 
1. Introduction 7 
The plant Cannabis sativa has been used for medicinal purposes for thousands of years by different 8 
cultures [1]. Cannabis extract contains more than 80 components, of which Δ9-tetrahydrocannabinol (D9-9 
THC), the main psychoactive ingredient) and cannabidiol (CBD) are the most abundant [2,3]. These 10 
compounds were first identified several decades ago [4], but it is only more recently that the discovery of 11 
cannabinoid receptors and their endogenous homologues, the endocannabinoids [5] such as N-12 
arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) [6], has occurred. 13 
Together with their related enzymes, endocannabinoids and their receptors form the endocannabinoid 14 
system (ECS) (Fig 1) [7]. Cannabinoids – both endogenous and plant-derived – target the G protein-15 
coupled cannabinoid receptors type-1 (CB1), which is widely expressed in the nervous system, and type-2 16 
(CB2), which is mainly expressed in immune cells [8,9]. Presently, it is proposed that the ECS has roles 17 
in the pathological mechanisms of several psychiatric disorders, including schizophrenia [10]. Besides, 18 
cannabinoids such as CBD also interact with a variety of non-endocannabinoid mechanisms, including 19 
numerous classical ion channels, receptors, transporters, and enzymes, as reviewed recently [11]. 20 
The effects of isolated cannabinoids and Cannabis extracts in different diseases have been studied for 21 
many years [12]. In the United States, recent medical and recreational marijuana legalization increased 22 
Cannabis accessibility and use [13]. Additionally, despite widely known deleterious effects during central 23 
nervous system development, medical marijuana usage by minors, with the consent from a legal guardian 24 
and certification from a physician, is approved [14]. Marijuana-derived products have their main effects 25 
against childhood severe epilepsies including Dravet and Lennox-Gastaut syndromes. These early onset 26 
disorders are characterized by frequent, refractory seizures and neurodevelopmental delays, which lead to 27 
impaired quality of life of these individuals. This scenario compels families to seek alternative treatment 28 
methods, such as CBD-based therapies, which include pure synthetic or plant-derived CBD and CBD-29 
enriched Cannabis extracts. In children, plant-derived pharmaceutical-grade isolated CBD has been tested 30 
   
 
   
 
4
in clinical trials in patients with such syndromes ([15–17]) and this drug (Epidiolex®) has recently been 1 
approved in the US as orphan drug for those syndromes. Clinical trials with synthetic isolated CBD are 2 
ongoing (clinicaltrials.gov website). In addition, reports on the use different form of Cannabis extracts in 3 
children with epilepsy have also been published [18–20]. However, only few adequately powered, 4 
placebo-controlled randomized studies have evaluated the safety and efficacy of CBD-based therapies in 5 
children [21]. Nevertheless, most of these have reported a greater reduction in convulsive-seizure 6 
frequency than placebo, however they were also associated with higher rates of adverse events [22].  7 
The constituents of the ECS, receptors and endocannabinoids, are expressed and are functional from very 8 
early developmental stages, whereby they regulate inhibitory and excitatory synapses. Even during 9 
adolescence, the brain and the ECS undergo active development which may confer increased 10 
vulnerability to adverse long-term outcomes from early cannabinoid exposure [23]. Endocannabinoids 11 
have been shown to regulate cortical development throughout life in humans, and exogenous 12 
cannabinoids can alter cortical development of both the somatosensory and the prefrontal cortex [24]. 13 
Nevertheless, the current widespread use of CBD-based therapies in children and young adults, without 14 
sufficient studies of the potential consequences upon neuronal and other systems' development, is of 15 
concern to the scientific and medical communities. One area of particular concern is the uncontrolled 16 
amount of D9-THC present in such extracts. Moreover, in 2017 an ad hoc committee of the National 17 
Academies of Sciences, Engineering, and Medicine presented a report regarding the health effects of 18 
Cannabis and CBD use, which revealed no or insufficient evidence to either support or refute the use of 19 
such compounds as an effective treatment for epilepsy [25]. Hence, this article reviews the current 20 
knowledge about the use of CBD-based therapies in pediatric patients, its alleged side effects, and its 21 
mechanisms of action regarding the central nervous system and neurodevelopmental aspects. We 22 
highlight that CBD administration before adulthood must be carefully evaluated, and the use of pure CBD 23 
and/or synthetic cannabinoids as a preferential alternative to Cannabis extracts for children and young 24 
adults needs to be studied further. 25 
 26 
2. The Endocannabinoid System 27 
Most cannabinoids exert their therapeutic properties upon the central nervous system primarily via the 28 
ECS,  although there are other known targets [26]. Here we discuss their effects upon the ECS. 29 
   
 
   
 
5
Endocannabinoid signaling plays crucial roles in various aspects of both the underdeveloped and the 1 
mature brain [27]. Therefore, disturbances in this system may disrupt neural development. 2 
The classical ECS signaling pathway is shown in Figure 1 (for review see [10]). In the mature brain, the 3 
ECS modulates synapses (excitatory and inhibitory) through the release of endocannabinoids AEA and 2-4 
AG. These act as retrograde messengers, their release by the postsynaptic neuron activating CB1 receptors 5 
in the pre-synaptic neuron, leading to decreased release of neurotransmitters into the synaptic cleft 6 
[10,28,29]. This process is initiated by increased Ca2+ influx caused by neurotransmission in the 7 
postsynaptic neuron which activates endocannabinoid synthesis from its precursors in the plasma 8 
membrane. AEA is generated from phospholipase D-mediated hydrolysis of the membrane lipid N-9 
arachidonoylphosphatidylethanolamine (NAPE), while 2-AG originates from the diacylglycerol lipase-10 
mediated hydrolysis of diacylglycerol (DAG), derived mainly from membrane-localized 11 
phosphatidylinositol biphosphate (PIP2). AEA and 2-AG diffuse towards the pre-synaptic terminals and, 12 
like exogenous cannabinoids such as D9-THC, bind to and activate the pre-synaptic G-protein-coupled 13 
CB1 receptors. This binding triggers the activation and release of Gi/Go proteins from the CB1, inhibiting 14 
adenylyl cyclase (AC) and thus decreasing cyclic AMP (cAMP) formation and subsequent protein kinase 15 
A (PKA) activity. These events lead to opening of inwardly-rectifying K+ channels, causing a 16 
hyperpolarization of the pre-synaptic terminal, and closing of Ca+2 channels, arresting the release of 17 
stored neurotransmitters. Finally, AEA and 2-AG re-enter the post- or pre-synaptic terminals, where they 18 
are catabolized respectively by fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), 19 
to yield either arachidonic acid (AA) and ethanolamine (ET) in the case of AEA, or AA and glycerol for 20 
2-AG. The transport of endocannabinoids through the plasma membrane is still not completely 21 
understood. Although some studies have proposed the existence of an endocannabinoid transporter, the 22 
trafficking of AEA, which has been most extensively studied, is proposed to occur through facilitated 23 
membrane transport followed by intracellular shuttling and sequestration [30]. 24 
Additionally, CB1 receptor activation leads to stimulation of mitogen-activated protein kinase (MAPK) 25 
activity, a mechanism by which cannabinoids affect synaptic plasticity, cell migration, and possibly 26 
neuronal growth [23]. In mature neurons, the MAPK cascade, which leads to the activation of 27 
extracellular signal-regulated kinases (ERK), is stimulated by excitatory glutamatergic signaling. 28 
Subsequently, ERK activity regulates two processes that underlie changes in synaptic transmission — the 29 
activity of postsynaptic AMPA receptors, and structural plasticity [31]. ECS retrograde signaling 30 
   
 
   
 
6
mediates synaptic plasticity through three classical mechanisms: depolarization-induced suppression of 1 
inhibition or excitation, metabotropic-induced suppression of inhibition or excitation, and 2 
endocannabinoid-mediated short-term depression or long-term depression (STD/LTD) [10]. Also, CB1 3 
agonists can prevent long-term potentiation (LTP) of synaptic transmission, but the influence of 4 
endogenously formed cannabinoids on hippocampal LTP remains ambiguous [32]. Both LTP and LTD 5 
have roles in learning and neural development [24]. 6 
Thus, the central component of the ECS in neurons is the CB1 receptor (Fig. 1). In the central nervous 7 
system, CB1 is particularly enriched in the cortex, hippocampus, amygdala, basal ganglia outflow tracts, 8 
and cerebellum. This distribution corresponds to the most prominent behavioral effects of Cannabis 9 
and helps to predict neurological and psychological effects of ECS manipulation [33]. CB1 receptors are 10 
also observed in intracellular compartments such as the mitochondrial surface, where they are able to 11 
activate G protein-dependent signaling and modify intracellular levels of ATP, Ca2+, and reactive oxygen 12 
species, all of which impact upon synaptic transmission [34].  13 
In the developing nervous system and the remaining neurogenic areas in the adult brain (the hippocampal 14 
subgranular zone and subventricular zone), the ECS exerts a regulatory role on neural progenitor cell 15 
survival, proliferation, differentiation and migration via CB1 [35,36], thus possibly affecting the 16 
formation of adult specialized tissues [37]. Recently, the ECS has also been shown to regulate 17 
proliferation and differentiation of mesoderm-derived hematopoietic and mesenchymal stem cells, with a 18 
key role in determining the formation of several cell types in peripheral tissues [38]. 19 
The importance of the ECS during embryonic development has been investigated through many 20 
experimental models and approaches, mainly focusing upon the deleterious effect of early D9-THC 21 
administration. For example, D9-THC administration to pregnant mice interfered with sub-cerebral 22 
projection neuron generation, thereby altering corticospinal connectivity, and produced long-lasting 23 
alterations in the fine motor performance and seizure susceptibility of the adult offspring. These 24 
deleterious consequences were solely attributed to D9-THC’s ability to disrupt the neurodevelopmental 25 
role of CB1 signaling [39]. 26 
During adolescence, the ECS has a role in the development of the cortex, amygdala, hippocampus and 27 
hypothalamus, and exogenous cannabinoids have long-term effects on cognition, anxiety and stress-28 
related behaviors, leading to mood disorders and substance abuse [24]. At this age, cannabinoids may 29 
produce abnormal LTD in prefrontal cortex by disrupting LTD mediated by metabotropic glutamate 30 
   
 
   
 
7
receptors and CB1 [40]. The ECS maintain the homeostasis of prefrontal cortex interactions with the 1 
amygdala and hippocampus, which are responsible for behaviors such as emotional memory and anxiety-2 
related behaviors. Endocannabinoids are required for the normal stress response, a process which matures 3 
during adolescence [24]. Besides, as the prefrontal cortex is the last brain region to finish development 4 
after adolescence, the abundance of CB1 receptors may explain the negative effects of Cannabis use in 5 
this age range [27]. Finally, endocannabinoids are necessary for the normal regulation of neuronal 6 
excitation and inhibition, hence disturbances in this delicate equilibrium likely result in changes in the 7 
balance of excitation/inhibition in individual neurons and networks, processes which are necessary for 8 
normal cortical development [24]. 9 
For therapeutic purposes, regarding the mature central nervous system, the ECS has shown to modulate 10 
anxiety, depression, neurogenesis, reward, cognition, learning, and memory [23]. Moreover, its retrograde 11 
signaling acts to regulate seizure activity and neuronal hyper-excitability – cannabinoids have shown CB1 12 
activity in experimental models of seizure and epilepsy [41,42]. However, the use of CB1 agonists such as 13 
D9-THC, or even Cannabis extract, as a therapeutic strategy is unfeasible due to their psychoactive 14 
effects, abuse potential and development of tolerance [42]. On the other hand, antagonism of CB1 can also 15 
exacerbate seizure activity in the epileptic phenotype [43]. 16 
Thus, the modulation of the ECS as a therapeutic approach is challenging because its blockage or its 17 
exacerbation could lead to undesired outcomes, especially during neuronal development. More studies are 18 
required to clarify its physiological functions and to predict the effect of CB1 agonists and antagonists, 19 
both in adult and pediatric patients, to support its targeting for therapeutic purposes. 20 
 21 
3. Therapeutic uses and mechanisms of action of CBD 22 
Cannabis causes many psychotropic effects, mainly mediated by D9-THC agonism of CB1 [44], which 23 
makes it unlikely to be used in natura. On the other hand, experimental studies have demonstrated several 24 
therapeutic properties of isolated cannabinoids in a number of in vitro and in vivo models [45]. Here, we 25 
discuss the therapeutic uses of the most prominent of these cannabinoids, CBD, and its mechanisms of 26 
action, highlighting its activity towards the CB1 receptor. 27 
Although only a limited number of studies have focused upon CBD, recently it has been shown to be a 28 
potent anti-inflammatory and antioxidant agent and to attenuate the memory-impairing effects produced 29 
by D9-THC, amongst other effects [23]. This opens a wide range of possible therapeutic uses in 30 
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neurodegenerative disorders including Parkinson's disease, Alzheimer's disease and cerebral ischemia 1 
[46]. Moreover, CBD is anti-emetic [47], has antitumoral properties against many types of cancer [48] 2 
and is also suggested to have antipsychotic, anxiolytic and antidepressant effects [49]. Finally, as already 3 
mentioned above, numerous studies have shown CBD to have anticonvulsive properties [50]. 4 
CBD has been reported to have a large number of possible molecular targets other than the ECS in a wide 5 
range of medical conditions, raising the possibility of significant off target effects  [26]. For instance, 6 
CBD is described as a full 5-HT1A agonist, a weak partial 5-HT2A agonist and a non-competitive 5-7 
HT3A antagonist [51]. The ability of CBD to activate the A1A adenosine receptor has also been reported 8 
[52]. CBD may play a role in the regulation of T-type calcium channels and the activity of nuclear 9 
peroxisome proliferator-activated receptor-γ (PPARγ), both of which have been implicated in seizure 10 
activity [53]. Other molecular targets have also been studied, among them the PPARγ nuclear receptors 11 
[54], glycine receptors [55], GABAA receptors [56], and transient receptor potential (TRP) channels [57]. 12 
Studies focused on the possible epigenetic regulation of skin differentiation genes by CBD revealed that it 13 
can act as a transcriptional repressor, controlling cell proliferation and differentiation through DNA 14 
methylation [58]. Hence, the molecular mechanistic basis for the effects of CBD appear to be complex, 15 
and thus remain to be fully elucidated. 16 
Although current evidence suggests that CBD does not directly interact with the ECS except in vitro at 17 
supraphysiological concentrations [11], it can also indirectly act as agonist or antagonist of the CB1 18 
receptor. In the nanomolar range (below the reported affinity (Ki) for CBD to these receptors), CBD can 19 
antagonize the pharmacological effects of CB1 agonists such as D9-THC and AEA, despite having low 20 
direct affinity in the micromolar range for CB1 in vitro [59,60]. McPartland et al reviewed in vitro and ex 21 
vivo mechanistic studies of CBD and found one study that reported slight agonism, and one study that 22 
reported slightly inverse agonism comprising binding to the inactive form of the receptor, blocking 23 
agonist effects, both of which occurred at high concentrations of CBD (≥10 µM). Surprisingly, in some 24 
mechanistic studies, the effects of CBD could be reversed by CB1 receptor inverse agonists, or were 25 
absent in CB1 receptor knockout mice [59]. This suggests that CBD may exert indirect agonism, 26 
comprising the enhancing of the effect of a receptor’s agonist without having any direct agonist effect 27 
itself, at CB1 receptors – either augmenting CB1 constitutional activity [61], or augmenting 28 
endocannabinoid tone through inhibition of AEA hydrolysis, inhibition of the putative AEA transporter 29 
and increase of 2-AG levels [59].  30 
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Recent evidence supports the hypothesis that CBD also binds to an allosteric site on CB1 receptors that is 1 
functionally distinct from the orthosteric site for its agonists. CBD reduced the potency and efficacy of 2 
CB1 agonists at concentrations lower than the predicted affinity of CBD for the orthosteric site of CB1 3 
receptors [62]. The presence of this allosteric site is still to be directly demonstrated due to difficulties in 4 
the resolution of the crystallographic structure of this receptor [63]. Despite such methodological issues, 5 
in vitro pharmacological experiments have demonstrated that, at very low concentrations, CBD is a 6 
negative allosteric modulator of CB1 [62]. 7 
Therefore, depending on the conditions, CBD seems to be able to interact both directly and indirectly 8 
with the CB1 receptor, via the regulation of endocannabinoids levels. Thus, since the ECS has a broad 9 
spectrum of physiological functions during neural development, it is reasonable to assume that CBD is 10 
potentially able interfere with processes regulated by CB1 when administered in infants. In fact, 11 
depending on the dosage and the clinical condition, potential CBD activity over CB1 (agonism or 12 
antagonism) results in different outcomes – either therapeutic or harmful [27], therefore its use must be 13 
very carefully considered in such ages. Besides, as CBD has effects upon other targets at lower 14 
concentrations, the mechanisms underlying its therapeutic properties are not yet clearly understood [42]. 15 
 16 
4. Studies with CBD-enriched Cannabis extracts and pure CDB in pediatric patients 17 
Currently, CBD is clinically used in association with D9-THC in a Cannabis-based preparation (Sativex®) 18 
that contains equimolar content of both, for the management of neuropathic symptoms associated with 19 
multiple sclerosis [64]. Relieve of spasticity and pain have been reported for multiple sclerosis patients 20 
that smoke Cannabis, but, for these patients, structural MRI scans have suggested reduced brain volume 21 
is associated with cognitive impairment [65]. Likewise, in recreational users, Cannabis has been shown to 22 
result in volumetric, gray matter and white matter structural changes in the brain, in particular in the 23 
hippocampus and the amygdala [66], further evidence that Cannabis (smoked and possibly in extracts) 24 
can be harmful in adult brain. 25 
In 2016, GW pharmaceuticals reported the first results of pure CBD (Epidiolex®) in phase III clinical 26 
trials for use in treatment-resistant seizure disorders, including Lennox–Gastaut and Dravet syndromes 27 
[17,22]. More recently, the same authors have released a further results of a randomized, double-blind, 28 
placebo-controlled trial using pure CBD [67,68]. Moreover, CBD-enriched Cannabis extract is still 29 
widely used as a therapeutic option. In this section, we review the available data on clinical trials, case 30 
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reports and parental surveys available from January 2000 to May 2018. We focused on literature 1 
containing data about isolated CDB administration and relevant oral Cannabis extracts with high CBD 2 
content in pediatric and young patients, as well as relevant studies on adult volunteer. 3 
The use of common Cannabis extracts is not recommended in children and adolescent patients due to the 4 
potential for deleterious effects. Fetal development is affected by prenatal maternal Cannabis use, while 5 
during infancy there is a negative impact upon cognitive and behavioral outcomes [69]. Early exposure to 6 
cannabinoids, mainly D9-THC, can impair all stages of memory, from encoding to consolidation and 7 
retrieval [70]. Additionally, Cannabis usage during adolescence increases the risk of developing 8 
psychotic disorders such as schizophrenia later in life [71,72]. Nevertheless, these effects are mainly 9 
associated with D9-THC, and CBD is able to counteract such effects [73]. This indicates that pure CBD 10 
would be a better therapeutic option instead of CBD-enriched or common Cannabis extracts. Careful 11 
consideration and attention should be taken when using CBD-enriched Cannabis extracts, in particular 12 
within pediatric contexts. In a recent case report, for example, two children presented typical symptoms 13 
of D9-THC intoxication (inappropriate laughter, ataxia, reduced attention, and eye redness) after using a 14 
CBD-enriched Cannabis extract. The extract was replaced by the same dose of purified CBD, resulting in 15 
decreased intoxication symptoms and seizure remission [74]. 16 
Table 1 summarizes the main findings in children and young adult patients treated with pure CBD and 17 
CBD-enriched Cannabis extract. As most studies that established safety and dose tolerance were 18 
performed in adults, they were also reviewed (supplementary table 1). The majority of published articles 19 
focused on neurological and neuropsychiatric conditions. In adult volunteers, CBD presented few adverse 20 
events and appeared to be safe, although its effectiveness was not always confirmed. In most of these 21 
studies, CBD was administered in a single dose. A recent article on the safety and tolerability of pure 22 
CBD in 34 children between 4 – 10 years old with Dravet Syndrome showed that CBD did not alter 23 
plasma antileptic drug levels, when randomized into different dosages or placebo for 3 weeks of treatment 24 
followed by a 4 week follow-up period [16]. The main adverse effects were pyrexia, somnolence, 25 
decreased appetite, sedation, vomiting, ataxia, and abnormal behavior. As observed in the studies above 26 
mentioned, and reviewed by Wong and Wilens (2017), the methodological quality of those clinical 27 
studies varied significantly (e.g. studies lacking control groups; limited by small sample size). Studies are 28 
also heterogeneous in the dosage and duration of treatment, and many lack any long-term follow-up 29 
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reviews to identify potential adverse effects [13]. This variability in protocols employed makes it difficult 1 
to evaluate the real benefits and risks of CBD-based therapies.  2 
Until a few years ago, the suggested beneficial outcomes of CBD-based therapies for pediatric patients 3 
were based mainly upon case reports and surveys of parents with epileptic children (supplementary table 4 
2). Such anedoctal studies were the first to report improvement in general condition of children with 5 
refractory epilepsies by Cannabis extracts, and so they attracted the interest of the scientific community 6 
for cannabinoids-based treatments. Many surveys of parents of children with refractory seizures who self-7 
administered CBD-enriched Cannabis extracts have been published in the last decades. One such survey, 8 
involving a small cohort of patients, showed that 42% of children had a greater than 80% reduction in 9 
seizure frequency [75]. Another survey, using a larger cohort of 75 pediatric patients, reported that 38% 10 
of children achieved greater than 50% reduction in seizures [20]. An online survey of 117 parents of 11 
children with epilepsy reported that 85% of children had a reduction in seizure frequency, whilst 14% 12 
reported complete freedom from seizure after CBD-enriched Cannabis treatment [19]. These surveys, 13 
even though not controlled, reported general improvements in cognitive and motor function in patients 14 
undergoing CBD-based therapies, along with some mild side effects.  15 
On the other hand, not all studies have reported favorable results (e.g. CBD-enriched Cannabis extract 16 
resulted in no improvement in general condition or seizure relief of an 18-year old male with severe 17 
refractory epilepsy) [76]. Moreover, case reports and parent surveys rarely describe side effects or even 18 
drug administration issues. For this reason, clinical trials are indispensable for investigating both the 19 
therapeutic and toxicological aspects of CBD-based therapies, as well in standardizing drug 20 
administration protocols to allow direct study comparisons. 21 
However, as anedoctal studies have stimulated a growing interest in the anticonvulsive properties of 22 
CBD, pure CBD or CBD-enriched Cannabis extracts are now being tested in controlled clinical trials, 23 
with relevant positive outcomes thus far reported (table 1). Such studies are still somewhat limited in 24 
number, however a brief survey on clinicaltrials.gov website report at least 20 clinical trials that are 25 
currently recruiting young patients or already in progress [77]. An open-label clinical trial of 214 patients 26 
(aged 1–30 years) with severe, intractable, childhood-onset, treatment-resistant epilepsy investigated the 27 
efficacy and safety of pure CBD. Patients in the efficacy analysis group reported a median reduction in 28 
monthly motor seizures of 36.5% compared to the placebo group. Adverse events were reported in 79% 29 
of the safety analysis group, and serious adverse events were reported in 30% of patients, including one 30 
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death — a sudden, unexpected death due to the patient’s epilepsy which was determined as unrelated to 1 
CBD. Twelve percent of patients had severe adverse events possibly related to CBD use, the most 2 
common of which was status epilepticus (6%). Three percent of patients discontinued treatment because 3 
of an adverse event [17]. 4 
A randomized placebo-controlled clinical trial of pure CBD reported a significant reduction in 5 
total seizures of all types. Although there was no significant reduction in non-convulsive seizures, they 6 
did demonstrate a greater reduction in convulsive seizure frequency, with 62% of patients reporting an 7 
improvement in overall condition, with 5% of patients becoming seizure-free. Adverse events included 8 
diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal liver function tests [22]. This report, 9 
however, did not evaluated possible drug-drug interactions between CBD and Clobazam, of which 65% 10 
of patients enrolled on the study were prescribed. CBD can increase plasma Clobazam concentrations 11 
[78], hence the beneficial effects of CBD may have arisen indirectly due to the increased pharmacological 12 
effects of Clobazam and not as a direct pharmacological effect of CBD itself. 13 
In 2018, a randomized, double-blind, placebo-controlled trial encompassing 24 clinical sites in the USA, 14 
the Netherlands, and Poland, was published. In this study, pure CBD (20 mg/kg/day) or placebo was 15 
administered to patients with treatment-resistant Lennox-Gastaut syndrome (aged 2–55 years) for 14 16 
weeks. Of the 171 randomly assigned patients that received CBD (n = 86) or placebo (n = 85), 14 patients 17 
in the CBD group and one in the placebo group discontinued study treatment. The monthly drop in 18 
seizure frequency was reduced by 43.9% in the CBD group and 21.8% in the placebo group. Adverse 19 
events, which were mostly mild or moderate, occurred in 86% of patients in the CBD group and in 69% 20 
of patients in the placebo group [67]. 21 
Another recent double-blind, placebo-controlled trial, in which 225 patients with the Lennox–Gastaut 22 
syndrome (age range of 2 to 55 years) were randomly assigned to receive CBD at 10 mg/kg/day, 20 23 
mg/kg/day, or placebo administered in two equally divided doses daily for 14 weeks, showed significant 24 
decreases in seizure frequency [68]. Seizure frequency decreased by 41.9% in the 20 mg cannabidiol 25 
group, 37.2% in the 10-mg cannabidiol group, and 17.2% in the placebo group. Six patients in the 20 mg 26 
cannabidiol group and one patient in the 10 mg cannabidiol group were withdrawn from the trial because 27 
of adverse events. Fourteen patients who received cannabidiol (9%) had elevated plasma liver 28 
aminotransferase levels. The most common adverse events among the patients in the cannabidiol groups 29 
were somnolence, decreased appetite, and diarrhea; these events occurred more frequently in the higher-30 
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dose group. Yet, even in these two recent clinical trials, although they are scientifically relevant and 1 
reliable, a longer treatment and follow-up period was missing. 2 
In general, in pediatric patient clinical trials, the most common side effects reported were either mild 3 
(somnolence, fatigue, altered appetite, weight gain/loss, diarrhea and other gastrointestinal disturbances, 4 
irritability) or serious (drowsiness/dizziness, ataxia, tremor, mental sedation), with severe adverse effects 5 
such as increased seizure frequency and worsening seizure phenotype also being observed. Alimentary 6 
effects can be explained by the presence of the ECS in the gastrointestinal tract, where it has effects on 7 
motility, inflammation and immunity, intestinal and gastric acid secretion, nociception and emesis 8 
pathways, and appetite control [79]. In the brain, ECS modulates several brain functions, such as 9 
memory, mood, food intake, pain perception and the sleep-wake cycle [80], which may explain, at least 10 
partially, the CNS-mediated adverse effects observed in clinical trials. Besides, as discussed above, other 11 
cannabinoids present in Cannabis extracts as well as CBD are able to interact and possibly disturb the 12 
important roles played by the ECS during neurodevelopmental stages. 13 
It is likely that non-endocannabinoid targets of CBD may explain some of the positive and adverse effects 14 
observed [11]. For example, in a mouse model of Dravet Syndrome, the beneficial effects of CBD on 15 
inhibitory neurotransmission were mimicked and blocked by an antagonist of the orphan G protein-16 
coupled receptor 55 (GPR55), suggesting that the therapeutic effects of CBD are mediated through this 17 
lipid-activated G protein-coupled receptor and thus identify it as a third cannabinoid receptor [81].  18 
A careful case-to-case evaluation on the risk/benefit balance of CBD usage must be taken, as in the most 19 
serious cases repetitive infantile seizures can cause severe developmental, cognitive and motor 20 
impairment. These are obviously more detrimental then the adverse effects and possible 21 
neurodevelopmental implications of CBD, hence CBD may be an attractive therapeutic option in these 22 
cases. 23 
Finally, CBD therapy does not always work for all patients. Also, some of the studies used CBD-enriched 24 
Cannabis extracts, which contains D9-THC. Even the ones with pure CBD, in controlled clinical trials, 25 
have short treatment periods and short follow-up periods, which will not reveal the possible long-term 26 
effects of CBD as well as possible developmental adverse effects. Hence, more clinical trials, with larger 27 
population sizes and longer chronic pure CBD administration, are warranted in order to clarify under 28 
which conditions it is worthwhile and safe to use. In addition, it is still unknown how CBD acts on 29 
hormones, hepatic enzymes, drug transporters, and its interactions with other drugs [12].  30 
   
 




5. CBD during development: effects in cell culture and animal models for the developing brain 2 
Despite the increasing use of CBD-based therapies in children and adolescents whose brains are still 3 
developing, most in vitro and in vivo studies use mature cells or adult animal models and are thus not 4 
faithful mimics of the juvenile CNS. Experiments with immature animals or cells have greater potential 5 
for identifying CBD’s effects and the molecular mechanisms by which such effects are mediated with 6 
greater relevance to juveniles. However, few studies have evaluated the developmental phases which are 7 
equivalent to human CNS development. Here, we present some of the recent studies using pure CBD in 8 
relevant cellular and animal models of the developing brain. 9 
In a genetic mouse model of Dravet Syndrome, caused by loss-of-function mutations in the voltage-gated 10 
sodium channel NaV1.1, CBD treatment from postnatal day 21 to 27 decreased the duration and severity 11 
of thermally-induced seizures and the frequency of spontaneous seizures. Lower doses of CBD also 12 
improved autistic-like social interaction deficits [81]. This mouse model represents a very specific cause 13 
of children refractory epilepsy, a single mutation in a sodium channel subunit, and its positive outcomes 14 
must be considered carefully when extrapolated to other pathologies. 15 
Single dose administration of CBD to newborn piglets shortly after hypoxia-ischemia had a protective 16 
effect upon neurons and astrocytes, preserved brain activity, prevented seizures and improved 17 
neurobehavioral performance [82,83]. In newborn rat brains, CBD administration also prevented necrotic 18 
and apoptotic cell death in an in vivo model of hypoxia-ischemia damage [84], and rescued neuron 19 
function after sciatic nerve transection [85]. However, both studies used a single dose of CBD at a very 20 
specific moment, namely immediately after an intensive brain injury, to evaluate its acute effects. Thus, 21 
these results may not be representative of long-term treatments with CBD. 22 
Although recent literature has primarily searched for protective and therapeutic potentials of CBD, a 23 
recent research paper has reported negative effects. Zebrafish, exposed from blastula through to larval 24 
stage to micromolar concentrations of D9-THC (1-16 µM) or CBD (0.25-4 µM), presented similarity in 25 
dysmorphologies to both compounds (i.e., edemas, curved axis, eye/snout/jaw/trunk/fin deformities, 26 
swim bladder distention, and behavioral abnormalities), whilst the LC50 for CBD was nearly seven times 27 
lower than D9-THC. The authors also reported teratogenic effects of low concentrations of CBD. [86]. In 28 
contrast, another research found no malformation in development of zebrafish embryos exposed to CBD 29 
20–300 µg/L, although the maximal dosage caused delay in embryo hatching. Besides, they were 30 
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temporarily more active than control. The authors discussed that the effects observed are intimately 1 
related to CB1 receptor [87]. Again, the chosen doses may be responsible for the difference in results 2 
observed in these two studies. Additionally, 10 µM of D9-THC, but not 10 µM of CBD, arrested the 3 
development of preimplantation mouse embryos [88]. 4 
Notwithstanding that very few studies offer insight into CBD toxicity, some deleterious effects have been 5 
reported for CBD in vitro and in vivo. These include alterations in cell viability, reduced fertilization 6 
capacity, and inhibition of hepatic drug metabolism and drug transporters [89]. Our research group 7 
showed, in a study using an in vitro model of human neurons (human neuroblastoma SH-SY5Y cells 8 
differentiated with retinoid acid), that a sublethal dose of CBD with antioxidant activity did not exhibit 9 
neuroprotection against the neurotoxic effect of glycolaldehyde, methylglyoxal, 6-hydroxydopamine, and 10 
hydrogen peroxide in terminally-differentiated neurons. When SH-SY5Y cells undergoing neuronal 11 
differentiation were exposed to the same dose of CBD, besides the lack of neuroprotection and 12 
antioxidant activity, CBD potentiated the neurotoxicity induced by all redox-active drugs tested [90]. 13 
These results suggest a possible hidden negative effect of CBD during neuronal development, reinforcing 14 
the observation that effective dosages for CBD and the resulting pathologies observed can vary widely 15 
according to the experimental model used. 16 
Thus, pure CBD present both positive and deleterious effects in animal and cellular models of early 17 
stages of development. We recommend that the therapeutic use of CBD and other cannabinoids during 18 
brain developmental stages must be always supported by experimental studies in appropriate cellular and 19 
animal models, with a special attention to the therapeutic window of CBD. It is particularly important to 20 
consider that the effect of CBD in humans follows an inverted U-shaped dose-effect curve pattern of 21 
effectiveness observed in many animal studies [91,92]. 22 
  23 
6. Therapeutic perspectives 24 
Although a number of physiological effects of CBD in the brain have been identified, the mechanism(s) 25 
underlying its therapeutic properties in neurological diseases and during neurodevelopment are not yet 26 
clearly understood. Depending on the experimental model, the dosage used and the protocol, CBD can act 27 
upon CB1 as an agonist, or as an antagonist of endogenous ligands, or as an allosteric modulator, as well 28 
as acting upon non-endocannabinoid targets. Nevertheless, D9-THC, which is able to interact with the 29 
ECS, is present in CBD-enriched Cannabis extracts used in some studies. Since the ECS performs 30 
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primordial functions during embryonic development and neurodevelopment, in addition to neurogenesis 1 
in adults, it makes sense to hypothesize that any molecule that disturbs ECS activity, such as D9-THC 2 
(and potentially CBD), might disrupt the processes regulated by this cellular signaling system. 3 
Regarding CBD therapeutic use for the treatment of children, there are several positive results in clinical 4 
trials and case reports in children with refractory epilepsy. However, for CBD-enriched Cannabis extracts 5 
the controversial effects of D9-THC points to a possible risk of adverse effects for its use in young 6 
patients. Cannabis has been associated with development of psychotic symptoms later in life, and a recent 7 
publication was able to establish a causal role of Cannabis use during adolescence and the emergence of 8 
such symptoms in the subsequent year [72]. Such effects are attributed to D9-THC activity on CB1. As 9 
CBD has low affinity for CB1, although it interferes in other steps of ECS signaling, this cannabinoid may 10 
be preferable and safer. Thus, formulations containing D9-THC should be avoided. Moreover, adverse 11 
effects of CBD and its extracts – even though they are mainly not severe – as well as absence of 12 
therapeutic effects were also reported. Seizure reduction has a significant effect on the patient’s quality of 13 
life, but the need to take into account other changes that CBD could cause in social behavior, cognitive 14 
function, or motor skills, is also important. Another concern is that the use of CBD-based therapies for 15 
pediatric epilepsy and anxiety (see table 1 and supplementary table 2), together with the common belief 16 
that natural products are always harmless, could represent a precedent for its use to treat other 17 
neurological diseases. It is not completely clear how CBD affects children’s brain development and how 18 
it could represent any probability of developing diseases later in adulthood. Thus, despite evidences for 19 
potential benefits in pediatric patients, pediatricians and families must balance the decision to use CBD 20 
with the associated risks [13]. An evaluation must occur on a case-to-case basis, with each instance 21 
considering the damage to the patient that may arise from uncontrolled epileptic seizures, the adverse 22 
effects of the established antiepileptic drugs and the uncertainties in the effects of CBD during brain 23 
development. 24 
Recently, natural and synthetic derivatives of CBD have attracted the attention of both industry and 25 
academia. Indeed, some of these molecules are being studied for a variety of purposes, most of them 26 
aiming to improve the potency, efficacy, or pharmacokinetic properties of CBD [93]. For instance, a 27 
natural CBD derivative, cannabidiolic acid (CBDA), does not have effect on inhibition of anandamide 28 
uptake while keeping the low CB1 affinity [93]. Thus, CBDA probably does not interfere in ECS 29 
signaling, what lowers the risk for adverse effects during brain development. The conversion of oral CBD 30 
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into D9-THC in an acidic environment (e.g. the stomach) is another concern, although it has not been 1 
observed in vivo thus far [94]. A novel CBD derivative, HU-444, is a potential novel drug which cannot 2 
be converted by acid cyclization into a D9-THC–like compound. In vitro, HU-444 has an anti-3 
inflammatory activity, leading to the suppression of TNF-α production and amelioration of liver damage, 4 
whilst not causing D9-THC-like effects in mice [95]. Another synthetic cannabinoid, HU-320, produced 5 
strong anti-inflammatory and immunosuppressive effects in an in vivo model of collagen-induced arthritis 6 
[95]. 7 
For the generation of another class of CBD derivatives, the introduction of the DMH alkyl chain in the (-8 
)-DMH-CBD series did not alter the lack of CB1 and CB2 receptor affinity [96]. (-)-DMH-CBD analogs 9 
have displayed anxiolytic, analgesic, anti-inflammatory, and antiproliferative effects in diverse assays 10 
[93]. (-)-DMH-CBD has been shown to have anti-inflammatory and antiproliferative properties in human 11 
acute myeloid leukemia [97]. Interestingly, (-)-7-OH-DMH-CBD exhibited potent inhibition of 12 
electrically-evoked contractions of the mouse vas deferens that was not mediated through CB1, CB2, 13 
TRPV1, opioid, or α2-adrenergic receptors [98,99]. 14 
Measurements of the binding affinities for the CB1 and CB2 cannabinoid receptors yielded unexpected 15 
outcomes of some CBD enantiomers. Contrary to naturally occurring (-)-CBD analogs, some synthetic 16 
derivatives, such as (+)-CBD, H2-CBD, H4-CBD, and HU-465 bind to CB1 and several of them have 17 
shown interesting pharmacological properties for various pathologies [93]. However, as CB1 activity is 18 
not desirable for an antiepileptic drug due to all the ECS roles at developmental stages, such derivatives 19 
might not be an alternative in these cases. Thus, likewise natural occurring cannabinoids, different CBD 20 
derivatives vary in their pharmacological and therapeutic properties, evidencing the need for a better 21 
understanding of their mechanism of action. 22 
 23 
7. Conclusion 24 
As Cannabis extracts contain D9-THC, which has psychoactive effects and is a CB1 agonist and may 25 
potentially disturb the ECS processes during brain development, pure GMP-grade CBD, synthetic or 26 
plant derived, is probably a safer option for use in pediatric and juvenile patients. Recently, a CBD oral 27 
solution, purified from a Cannabis extract, and developed and tested by GW Research has been approved 28 
by the Food and Drug Administration agency of United States (FDA), as an adjuvant in the treatment of 29 
seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years of age and 30 
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older. According to the released document, the approval was based on CBD’s effectiveness in preclinical 1 
and clinical trials and due to its mechanisms of action (low CB1 affinity, reduction of neuronal 2 
hyperexcitability and inflammation) [100]. 3 
However, since CBD can potentially affect the ECS also, further studies are recommended in order to 4 
clarify its mechanisms of action and developmental implications. Besides, longer chronic treatment and 5 
follow-up periods are recommended in clinical trials and animal studies in order to evaluate CBD’s long-6 
term effects, as well as the most effective dosage and the age which the therapeutic use of pure CBD is 7 
not only effective but also safe.  8 
At the moment, we consider that CBD is recommended as the last option for the treatment of non-9 
responsive epileptic children. For other neurological or psychiatric diseases, such as childhood anxiety, 10 
there is insufficient evidence to support the effectiveness of CBD. Besides, we suggest that more studies 11 
should use adequate experimental models to focus on pure CBD, in order to establish its safe and 12 
effective dosage and therapeutic targets, as well as synthetic CBD derivatives, aiming to identify a CBD 13 
analog with therapeutic properties but with fewer risks to the developing brain. 14 
 15 
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Figure Legends: 20 
Fig. 1 Retrograde endocannabinoid signaling. Endocannabinoids are produced on demand in the post-21 
synaptic neuron, released in the synaptic cleft and activate CB1 receptor in the pre-synaptic neuron. 22 
Reactive oxygen species (ROS); endocannabinoid system (ECS); anandamide (AEA); 2-23 
arachydonoilglycerol (2-AG); N-arachidonoylphosphatidylethanolamine (NAPE); N-24 
arachidonoylphosphatidylethanolamine phospholipase-D (NAPE-PLD); diacylglycerol (DAG); 25 
diacylglycerol lipase (DAGL); phosphatidylinositol biphosphate (PIP2); CB1 (CB1 receptor); adenylyl 26 
cyclase (AC), cyclic AMP (cAMP); protein kinase A (PKA); fatty acid amide hydrolase (FAAH); 27 
monoacylglycerol lipase (MAGL); arachidonic acid (AA); ethanolamine (ET); mitogen-activated protein 28 
kinase (MAPK). 29 
 30 
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Table 1. Clinical trials using pure CBD published until May 2018 with children and young patients 1 
 2 
Suplementary Table 1. Adult volunteer studies on adverse effects of pure CBD and relevant CBD-3 
enriched extract (CBD-based therapies) 4 
 5 
Supplementary Table 2. Pure CBD and relevant CBD-enriched extract (CBD-based therapies) case 6 
reports, parent surveys and retrospective chart reviews published until May 2018 with children and young 7 
adults8 
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